Article Information
History
- June 19, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Timothy L Wiemken, Ph.D.*,
- Farid Khan, MPH,
- Jennifer L Nguyen, ScD,
- Luis Jodar, Ph.D. and
- John M McLaughlin, PhD*
- ↵*Corresponding Author: Timothy L Wiemken Ph.D. MPH Global Clinical Epidemiologist Pfizer Vaccines, 500 Arcola Rd., Collegeville, PA 19426 USA Phone: 314-285-7286, Email: timothy.wiemken{at}pfizer.com; Alternate Corresponding Author: John M McLaughlin, PhD, Vice President, Global Franchise Lead, COVID-19 and mRNA vaccines Pfizer Inc., 500 Arcola Rd, Collegeville, PA 19426, E: john.mclaughlin{at}pfizer.com
Posted June 19, 2022.
